Loading...
Market
First hospital to administer Leqembi in China by September 30, 2024
4
Resolution / Starting Odds
Peking Union Medical College Hospital • 25%
Huashan Hospital, Shanghai • 25%
West China Hospital, Sichuan University • 25%
Xiangya Hospital, Central South University • 25%
Public announcements or official hospital statements
Story
Eisai and Biogen Launch Alzheimer's Drug Leqembi in China at USD24,800 per Year
Jun 27, 2024, 11:37 PM
Eisai and Biogen have launched their Alzheimer's treatment Leqembi in China, marking the third country after the United States and Japan to approve the drug. The treatment, which was approved by the Chinese regulator in January, is expected to be put into clinical use in Chinese hospitals, according to a hospital staffer in Shanghai. Leqembi, also known as Lecanemab, will cost CNY180,000 (USD24,800) per one-year cycle. This development signifies a significant step in the availability of advanced Alzheimer's treatments in China.
View original story
Similar markets
Beijing • 25%
Shanghai • 25%
Guangzhou • 25%
Shenzhen • 25%
Beijing • 13%
Shanghai • 13%
Guangzhou • 13%
Shenzhen • 13%
Tianjin • 13%
Nanjing • 13%
Suzhou • 13%
Hainan • 13%
Yes • 50%
No • 50%
United States • 25%
Germany • 25%
United Kingdom • 25%
Japan • 25%
Yes • 50%
No • 50%
Mayo Clinic • 25%
Cleveland Clinic • 25%
Johns Hopkins Medicine • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Indonesian Hospital • 25%
Al-Awda Hospital • 25%
Shifa Hospital • 25%
Other • 25%
Yes • 50%
No • 50%
